pharma · Metastatic Melanoma · Unresectable Melanoma · IOVA
Iovance Biotherapeutics
Iovance Biotherapeutics B.V.
NovaPharmaNews editorial coverage mentioning Iovance Biotherapeutics — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 825 Industrial Rd, Suite 400, San Carlos, California 94070, US
- Founded
- 2007
- Employees
- 916
- Programs
- 36
- Drugs
- 26
- Patents
- 94
News & analysis
NovaPharmaNews articles mentioning Iovance Biotherapeutics — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Iovance Biotherapeutics — regulatory, clinical, and market analysis.
FDA Clears Iovance IL-12 TIL Trial, Signaling New Frontier in Solid Tumor Therapy
The FDA has cleared Iovance Biotherapeutics' Investigational New Drug application for IOV-5001, a novel IL-12 tethered TIL therapy designed for advanced solid tumors. This clearance allows for the initiation of a Phase 1/2 clinical trial, potentially expanding treatment options for patients with difficult-to-treat indications.
Biotech Movers: Moderna, Iovance, ALHC, and Summit Therapeutics in Focus
Biotech stocks showed mixed performance as Moderna advanced its Ebola vaccine efforts and Summit Therapeutics saw a surge on Phase 3 data. Meanwhile, Alignment Healthcare faced a downgrade, and Iovance Biotherapeutics remains a subject of analyst debate.